v::ALK

About

Gene context: ALK

Biomarker Type: Rearrangement

Present: True

Rearrangement Type: Fusion


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Lorlatinib FDA
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Lorlatinib HC
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Lorlatinib HC
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Alectinib HC
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Brigatinib HC
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Ceritinib FDA
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Crizotinib FDA
Sensitivity (+) v::ALK Anaplastic Large Cell Lymphoma Crizotinib FDA
Sensitivity (+) v::ALK Inflammatory Myofibroblastic Tumor Crizotinib FDA
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Crizotinib HC
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Brigatinib FDA
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Ensartinib FDA
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Atezolizumab FDA
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Ceritinib HC
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Ceritinib HC
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Alectinib FDA
Sensitivity (+) v::ALK Non-Small Cell Lung Cancer Alectinib FDA